A French medical laboratory and the European Commission are currently locked in a furious legal battle - at stake is whether a handful of EU civil servants, through use of byzantine rules, can defy medical opinion and keep a life-saving drug off the market.
The battle has been going on for three years.
The eventual court judgement will directly affect patients with a very rare genetic disease. More broadly, it will define the boundaries within which commission officials can play ...
Enjoy access to all articles and 25 years of archives, comment and gift articles. Become a member for as low as €1,75 per week.
Already a member? Login